{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-018358","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.240238+00:00","generated_at":"2026-05-20T14:30:21.280353+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Moleculin Biotech receives Nasdaq delisting notice for failing minimum stockholders' equity rule","bullets":["Nasdaq notified Moleculin on May 23, 2025, that it does not meet Listing Rule 5550(b)(1) requiring $2.5M in stockholders' equity.","The company has 45 calendar days to submit a plan to regain compliance; if accepted, a 180-day extension may be granted.","Failure to regain compliance could lead to delisting from the Nasdaq Capital Market; no immediate effect on trading.","The company may appeal any adverse Staff determination to the Nasdaq Hearings Panel."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-018358","json":"https://secwatch.observer/filing/0001437749-25-018358.json","markdown":"https://secwatch.observer/filing/0001437749-25-018358.md","text":"https://secwatch.observer/filing/0001437749-25-018358.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925018358/0001437749-25-018358-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925018358/mbrx20250523_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T14:30:21.280353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c805bceed5dba673927eaf82b719997ad8d931f5","claim":"Moleculin Biotech, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"May 23, 2025, Moleculin Biotech, Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does not h","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925018358/0001437749-25-018358-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}